Complex sets of miRNAs as non-invasive biomarkers for kidney cancer
AssigneeHummingbird Diagnostics GmbH
InventorsAndreas Keller, Markus Beier, Eckart Meese, Petra Leidinger, Anke Wendschlag
Life of this patent
Estimating the term…
Abstract
The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject.
Claims6
A method for diagnosing and/or prognosing of kidney cancer comprising the steps of:
- (i) determining an expression profile of a set comprising at least two miRNAs representative for kidney cancer in all blood cells of leukocytes, erythrocytes, and platelets without the acellular portion of a blood sample from a subject, and
- (ii) comparing said expression profile to a reference, wherein the comparison of said expression profile to said reference allows for the diagnosis and/or prognosis of kidney cancer,
- wherein kidney cancer is a renal cell carcinoma and the nucleotide sequences of the miRNAs comprised in the set are selected from the group consisting of SEQ ID NO:
- 1 to 465.
A kit for diagnosing and/or prognosing of kidney cancer comprising
- (i) means for determining an expression profile of a set comprising at least two miRNAs representative for kidney cancer in all blood cells of leukocytes, erythrocytes, and platelets without the acellular portion of a blood sample from a subject comprising:
- (a) a set of at least two polynucleotides or set of at least two primer pairs for detecting a set comprising at least two miRNAs for diagnosing and/or prognosing of kidney cancer in a blood sample from a subject, wherein the nucleotide sequences of the miRNAs comprised in the set are selected from the group consisting of SEQ ID NO:
- 1 to 465,
- (b) a biochip, a RT-PCR system, a PCR-system, a flow cytometer, a bead-based multiplex system or a next generation sequencing system,
- and
- (ii) at least one reference
- wherein kidney cancer is a renal cell carcinoma.
Dependencies are inferred from the claim text.